[Skip to Content]
[Skip to Content Landing]
Medical News & Perspectives
June 4, 2003

A Host of Novel Agents for Treating Psoriasis, Psoriatic Arthritis Stir Interest

JAMA. 2003;289(21):2779-2783. doi:10.1001/jama.289.21.2779

San Francisco—A host of novel medications that have been developed with recombinant DNA techniques are offering physicians new options for treating psoriasis and psoriatic arthritis that cannot be well controlled by standard therapies. An estimated 30% of the 5.5 million people of all ages with psoriasis in the United States experience the moderate-to-severe form of the illness that these new agents are designed to treat.